Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Steve Doberstein"'
Autor:
Kevin Fitzgerald, Svetlana Tertyshnikova, Lisa Moore, Lynn Bjerke, Ben Burley, Jian Cao, Pamela Carroll, Robert Choy, Steve Doberstein, Yves Dubaquie, Yvonne Franke, Jenny Kopczynski, Hendrik Korswagen, Stanley R Krystek, Nicholas J Lodge, Ronald Plasterk, John Starrett, Terry Stouch, George Thalody, Honey Wayne, Alexander van der Linden, Yongmei Zhang, Stephen G Walker, Mark Cockett, Judi Wardwell-Swanson, Petra Ross-Macdonald, Rachel M Kindt
Publikováno v:
PLoS Genetics, Vol 2, Iss 4, p e57 (2006)
We report here on a chemical genetic screen designed to address the mechanism of action of a small molecule. Small molecules that were active in models of urinary incontinence were tested on the nematode Caenorhabditis elegans, and the resulting phen
Externí odkaz:
https://doaj.org/article/1932641b9cd346b58d4f8941da49cf1f
Autor:
Steve Doberstein, Phi Quatch, Werner Rubas, Rhoneil Pena, Christie Fanton, Bo-Liang Deng, Yolanda Kirksey, Wen Zhang, Neel K. Anand, Marlene Hennessy, Janet Cetz, Cai Haiying, Wildaliz Nieves, John L. Langowski, Jonathan Zalevsky, Zhongxu Ren, Saul Kivimae
Publikováno v:
Cancer Research. 78:3755-3755
Background: NKTR-262 is a novel therapeutic, which delivers intratumoral engagement of the TLR 7/8 pathway, promoting an immune stimulatory environment and local injection site tumor antigen release. When NKTR-262 is administered in combination with
Autor:
Ute Hoch, Samira Khalili, Deborah H. Charych, Thomas Chang, Vidula Dixit, Aleksandrs Odinecs, John L. Langowski, Peter Kirk, Jonathan Zalevsky, Werner Rubas, Michael A. Eldon, Steve Doberstein
Publikováno v:
Cancer Research. 77:1617-1617
Introduction: NKTR-214 is a biologic prodrug currently in a Phase 1 / 2 clinical trial in patients with solid tumors, as a single agent and in combination with anti-PD1. It is a CD122-biased cytokine agonist conjugated with multiple releasable chains
Publikováno v:
Molecular Cancer Therapeutics. 14:C54-C54
Introduction: Talazoparib (BMN 673) is a highly potent and specific PARP1/2 inhibitor (PARPi) that has demonstrated significant clinical activity in patients with germline BRCA mutation ovarian and breast cancer, as well as in patients with small cel
Publikováno v:
Methods of biochemical analysis. 45
Publikováno v:
Development (Cambridge, England). 132(12)
Anillin is a conserved component of the contractile ring that is essential for cytokinesis, and physically interacts with three conserved cleavage furrow proteins, F-actin, myosin II and septins in biochemical assays. We demonstrate that the Drosophi
Autor:
May Ji, Thomas Linnemann, Lewis T. Williams, Keting Chu, Ernestine Lee, Robert Halenbeck, Kevin Hestir, Dirk Behrens, Cindy Leo, Haishan Lin, Scott Giese, Aileen Zhou, Minmei Huang, Steve Doberstein, Ge Wu, Elizabeth Bosch, Diane Hollenbaugh, Minmin Qin
Publikováno v:
Cytokine. 39:24
Autor:
May Ji, Hongbing Zhang, Aileen Zhou, Diane Hollenbaugh, Yan Wang, Thomas Linnemann, Lewis T. Williams, Elizabeth Bosch, Robert Halenbeck, Justin J.-L. Wong, Ernestine Lee, Steve Doberstein, Min Mei Huang, Haishan Lin, Minmin Qin, Scott Giese, Ge Wu, Kevin Hestir, Dirk Behrens, Cindy Leo, Amber Pham, Katrina Justin, Keting Chu
Publikováno v:
Blood. 108:634-634
To identify novel protein therapeutics we have utilized an integrated screening system in which a collection of full-length human cDNA clones, encoding virtually all secreted proteins and receptors, was assembled. Soluble secreted proteins were expre
Autor:
Robert Choy, Stephen G. Walker, Nicholas J. Lodge, Pamela M. Carroll, Jian Cao, Yvonne Franke, Lynn Margaret Bjerke, George Thalody, Lisa Moore, Yongmei Zhang, Mark I. Cockett, Rachel M. Kindt, Yves Dubaquie, Svetlana Tertyshnikova, Stanley R. Krystek, Petra Ross-Macdonald, Honey Wayne, Alexander M. van der Linden, Hendrik C. Korswagen, Steve Doberstein, Ronald H.A. Plasterk, Ben Burley, John E. Starrett, Terry R. Stouch, Jenny Kopczynski, Judi Wardwell-Swanson, Kevin Fitzgerald
Publikováno v:
PLoS Genetics, Vol 2, Iss 4, p e57 (2006)
PLoS Genetics
PLoS Genetics
We report here on a chemical genetic screen designed to address the mechanism of action of a small molecule. Small molecules that were active in models of urinary incontinence were tested on the nematode Caenorhabditis elegans, and the resulting phen